The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 26, 2016

Filed:

Aug. 08, 2012
Applicants:

Sung Wuk Kim, Seongnam-si, KR;

Chang Hee Min, Seoul, KR;

SE Hwan Park, Daejeon, KR;

Duck Kim, Daegu, KR;

Ji Sun Lee, Daejeon, KR;

Yong Eun Kim, Daejeon, KR;

Ju Hoon OH, Gangneung-Si, KR;

Inventors:

Sung Wuk Kim, Seongnam-si, KR;

Chang Hee Min, Seoul, KR;

Se Hwan Park, Daejeon, KR;

Duck Kim, Daegu, KR;

Ji Sun Lee, Daejeon, KR;

Yong Eun Kim, Daejeon, KR;

Ju Hoon Oh, Gangneung-Si, KR;

Assignee:

IMMUNOMET THERAPEUTICS INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07C 279/26 (2006.01); C07C 29/16 (2006.01); C07D 205/04 (2006.01); C07D 213/40 (2006.01); C07D 295/215 (2006.01); C07D 333/20 (2006.01); C07D 307/52 (2006.01);
U.S. Cl.
CPC ...
C07D 295/215 (2013.01); C07D 205/04 (2013.01); C07D 213/40 (2013.01); C07D 307/52 (2013.01); C07D 333/20 (2013.01);
Abstract

A N1-cyclic amine-N5-substituted biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.


Find Patent Forward Citations

Loading…